Comparison and Effectiveness of Regadenoson Versus Dipyridamole on Stress Electrocardiographic Changes During Positron Emission Tomography Evaluation of Patients With Hypertrophic Cardiomyopathy

This publication has 16 references indexed in Scilit:

• PET/CT Assessment of Symptomatic Individuals with Obstructive and Nonobstructive Hypertrophic Cardiomyopathy
  Journal of Nuclear Medicine, 2012
• Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET
  European Journal of Nuclear Medicine and Molecular Imaging, 2011
• Effects of Age, Gender, Obesity, and Diabetes on the Efficacy and Safety of the Selective A2A Agonist Regadenoson Versus Adenosine in Myocardial Perfusion Imaging
  JACC: Cardiovascular Imaging, 2008
• Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial
  Journal of Nuclear Cardiology, 2007
• Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans
  Journal of Nuclear Cardiology, 2007
• Prognostic utility of single-photon emission computed tomography in adult patients with hypertrophic cardiomyopathy
  American Heart Journal, 2006
• Initial Clinical Experience With Regadenoson, a Novel Selective A2AAgonist for Pharmacologic Stress Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging
  JACC, 2005
• Novel Short-Acting A2A Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A2A Agonists
  The Journal of Pharmacology and Experimental Therapeutics, 2001
• Dipyridamole-Induced Ischemia as a Prognostic Marker of Future Adverse Cardiac Events in Adult Patients With Hypertrophic Cardiomyopathy
  Circulation, 1997
• ST-segment depression during adenosine infusion as a predictor of myocardial ischemia
  American Heart Journal, 1994